Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations
Por:
Bernardo-Castineira C, Valdes N, Celada L, Martinez A, Saenz-de-Santa-Maria I, Bayon G, Fernandez A, Sierra M, Fraga M, Astudillo A, Jimenez-Fonseca P, Ria J, Hevia M, Turienzo E, Bernardo C, Forga L, Tena I, Molina-Garrido M, Cacho L, Villabona C, Serrano T, Scola B, Chirivella I, del Olmo M, Menendez C, Navarro E, Tous M, Vallejo A, Athimulam S, Bancos I, Suarez C, Chiara M
Publicada:
1 nov 2019
Resumen:
Context: SDHB mutations are found in an increasing number of neoplasms, most notably in paragangliomas and pheochromocytomas (PPGLs). SDHB-PPGLs are slow-growing tumors, but similar to 50% of them may develop metastasis. The molecular basis of metastasis in these tumors is a long-standing and unresolved problem. Thus, a better understanding of the biology of metastasis is needed.
Objective: This study aimed to identify gene methylation changes relevant for metastatic SDHB-PPGLs.
Design: We performed genome-wide profiling of DNA methylation in diverse clinical and genetic PPGL subtypes, and validated protocadherin gamma-C3 (PCDHGC3) gene promoter methylation in metastatic SDHB-PPGLs.
Results: We define an epigenetic landscape specific for metastatic SDHB-PPGLs. DNA methylation levels were found significantly higher in metastatic SDHB-PPGLs than in SDHB-PPGLs without metastases. One such change included long-range de novo methylation of the PCDHA, PCDHB, and PCDHG gene clusters. High levels of PCDHGC3 promoter methylation were validated in primary metastatic SDHB-PPGLs, it was found amplified in the corresponding metastases, and it was significantly correlated with PCDHGC3 reduced expression. Interestingly, this epigenetic alteration could be detected in primary tumors that developed metastasis several years later. We also show that PCDHGC3 down regulation engages metastasis-initiating capabilities by promoting cell proliferation, migration, and invasion.
Conclusions: Our data provide a map of the DNA methylome episignature specific to an SDHB-mutated cancer and establish PCDHGC3 as a putative suppressor gene and a potential biomarker to identify patients with SDHB-mutated cancer at high risk of metastasis who might benefit from future targeted therapies.
Filiaciones:
Bernardo-Castineira C:
Hosp Univ Cent Asturias, Head & Neck Oncol Lab, Oviedo 33011, Spain
Inst Oncol Asturias, Oviedo 33006, Spain
Inst Sanit Res Principado Asturias, Oviedo 33011, Spain
Ctr Invest Biomed Red Oncol, Oviedo 33011, Spain
Valdes N:
Hosp Univ Cent Asturias, Serv Endocrinol & Nutr, Oviedo 33011, Spain
Celada L:
Hosp Univ Cent Asturias, Head & Neck Oncol Lab, Oviedo 33011, Spain
Inst Sanit Res Principado Asturias, Oviedo 33011, Spain
Ctr Invest Biomed Red Oncol, Oviedo 33011, Spain
Martinez A:
Inst Sanit Res Principado Asturias, Oviedo 33011, Spain
Saenz-de-Santa-Maria I:
Hosp Univ Cent Asturias, Head & Neck Oncol Lab, Oviedo 33011, Spain
Inst Oncol Asturias, Oviedo 33006, Spain
Inst Sanit Res Principado Asturias, Oviedo 33011, Spain
Bayon G:
Inst Sanit Res Principado Asturias, Oviedo 33011, Spain
Hosp Univ Cent Asturias, Canc Epigenet Lab, Oviedo 33011, Spain
Fernandez A:
Inst Sanit Res Principado Asturias, Oviedo 33011, Spain
Hosp Univ Cent Asturias, Canc Epigenet Lab, Oviedo 33011, Spain
Sierra M:
Inst Oncol Asturias, Oviedo 33006, Spain
Inst Sanit Res Principado Asturias, Oviedo 33011, Spain
Hosp Univ Cent Asturias, Canc Epigenet Lab, Oviedo 33011, Spain
Fraga M:
Inst Sanit Res Principado Asturias, Oviedo 33011, Spain
Univ Oviedo, Spanish Council Sci Res, Nanomat & Nanotechnol Res Ctr, Oviedo 33007, Spain
Astudillo A:
Inst Sanit Res Principado Asturias, Oviedo 33011, Spain
Hosp Univ Cent Asturias, Serv Pathol, Oviedo 33011, Spain
Jimenez-Fonseca P:
Inst Sanit Res Principado Asturias, Oviedo 33011, Spain
Hosp Univ Cent Asturias, Serv Med Oncol, Oviedo 33011, Spain
Ria J:
Hosp Univ Cent Asturias, Serv Neurosurg, Oviedo 33011, Spain
Hevia M:
Hosp Univ Cent Asturias, Serv Med Oncol, Oviedo 33011, Spain
Hosp Univ Cent Asturias, Serv Urol Surg, Oviedo 33011, Spain
Turienzo E:
Hosp Univ Cent Asturias, Serv Surg, Oviedo 33011, Spain
Bernardo C:
Hosp Univ Cent Asturias, Serv Surg, Oviedo 33011, Spain
Forga L:
Complejo Univ Navarra, Serv Endocrinol & Nutr, Pamplona 31008, Spain
Tena I:
Hosp Prov Castellon, Med Oncol Serv, Castellon de La Plana 12002, Spain
Molina-Garrido M:
Hosp Gen Virgen Luz, Unit Canc Elderly, Cuenca 16002, Spain
Villabona C:
Hosp Univ Bellvitge, Serv Endocrinol & Nutr, Barcelona 08907, Spain
Serrano T:
Hosp Univ Bellvitge, Serv Pathol, Barcelona 08907, Spain
Scola B:
Hosp Gregorio Maranon, Serv Head & Neck Surg, Madrid 28007, Spain
Chirivella I:
Hosp Clin Univ Valencia, Unit Genet Counsel Canc, Valencia 46010, Spain
del Olmo M:
Hosp Univ Le Fe, Serv Endocrinol & Nutr, Valencia 46026, Spain
Menendez C:
Hosp Cabuenes, Serv Pathol, Gijon 33394, Spain
Navarro E:
Hosp Univ Virgen Rod, Serv Endocrinol, Seville 41013, Spain
Tous M:
Hosp Virgen Macarena, Unidad Gest Clin Endocrinol & Nutr, Seville 41009, Spain
Vallejo A:
Hosp Virgen Macarena, Unidad Gest Clin Pathol, Seville 41009, Spain
Athimulam S:
Mayo Clin, Div Endocrinol Diabet Metab & Nutr, Rochester, MN 55905 USA
Bancos I:
Mayo Clin, Div Endocrinol Diabet Metab & Nutr, Rochester, MN 55905 USA
Suarez C:
Inst Oncol Asturias, Oviedo 33006, Spain
Inst Sanit Res Principado Asturias, Oviedo 33011, Spain
Chiara M:
Hosp Univ Cent Asturias, Head & Neck Oncol Lab, Oviedo 33011, Spain
Inst Oncol Asturias, Oviedo 33006, Spain
Inst Sanit Res Principado Asturias, Oviedo 33011, Spain
Ctr Invest Biomed Red Oncol, Oviedo 33011, Spain
|